Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
AssigneeHolobiome, Inc.
InventorsPhilip STRANDWITZ, Kim LEWIS
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating at least one symptom of a mental disorder or disease of the central nervous system in a subject by modulating the amount of GABA produced in the subject's gut. The present disclosure also relates to methods of culturing the bacterial strain new bacterial strains. Also disclosed are methods of identifying bacterial strains capable of producing GABA, and engineering strains to produce GABA.
Claims32
A therapeutic composition comprising at least one purified bacterial population consisting of bacteria that produce GABA in a subject in need thereof.
(canceled)
12-14. (canceled)
(canceled)
(canceled)
A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutic composition comprising at least one purified bacterial population consisting of bacteria that produces GABA in a subject in need thereof.
26-39. (canceled)
42-76. (canceled)
A method of culturing a GABA-dependent bacteria, comprising disposing at least one live GABA-dependent bacterial cell on a suitable substrate, and providing a source of GABA.
78-81. (canceled)
A method of identifying a bacterial strain or strains capable of producing GABA at a physiologically relevant pH of the human intestinal tract, comprising:
- (a) dispersing a sample believed to contain GABA-producing bacteria within a substrate, the substrate being at least partially permeable to GABA,
- (b) contacting the substrate loaded with potential GABA-producing bacteria with a GABA-dependent bacterium;
- and
- (c) identifying a GABA-producing bacteria by observing the formation of a colonies of the GABA-dependent bacteria around potential GABA-producing bacteria in the substrate.
83-85. (canceled)
Dependencies are inferred from the claim text.